PARP Inhibitors Clinical Pipeline | 30+ Companies, Including TESARO, AstraZeneca, and Sun BioPharma, Driving the Next Breakthroughs

The PARP Inhibitors market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'PARP Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline PARP Inhibitors therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PARP Inhibitors pipeline domain.

For PARP Inhibitors emerging drugs, the PARP Inhibitors pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the PARP Inhibitors Pipeline Report
• DelveInsight's PARP Inhibitors Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline drugs for PARP Inhibitors treatment.
• The leading PARP Inhibitors companies include TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others are evaluating their lead assets to improve the PARP Inhibitors treatment landscape.
• Key PARP Inhibitors pipeline therapies in various stages of development include AZD5305, Veliparib, Pamiparib, and others.
• In March 2025, Laekna announced FDA approval of the IND for LAE120, a USP1 inhibitor for advanced solid tumors. LAE120 demonstrated strong tumor inhibition in xenograft models like MDA-MB-436 and K562 and showed synergy with PARP inhibitors.
• In May 2024, Eisbach Bio GmbH announced that the FDA cleared the IND application for EIS-12656, a first-in-class allosteric ALC1 inhibitor, to treat solid tumors, including those resistant to PARP inhibitors.
• In September 2023, the FDA granted fast track designation to IDE161 for adult patients with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer with BRCA1/2 mutations, following progression after at least one hormonal therapy, a CDK4/6 inhibitor, and a PARP inhibitor.

Request a sample and discover the recent breakthroughs happening in the PARP Inhibitors pipeline landscape @ https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

PARP Inhibitors Overview
Poly (ADP-ribose) polymerase (PARP) refers to a family of proteins that share structural similarities and functional roles in DNA repair mechanisms. Each PARP protein consists of two ribose moieties and two phosphate groups per polymer unit. Among them, PARP1 and PARP2 play a crucial role in the base excision repair (BER) pathway, which repairs single-strand DNA breaks (SSBs). Discovered in 1963, PARP1 is the most extensively studied enzyme in this group. In 1980, Durkacz et al. proposed that modulating PARP1 activity could enhance the effects of alkylating chemotherapy agents. When PARP1 detects DNA damage, it binds to the site using its DNA-binding domain, synthesizes poly (ADP-ribose) (PAR), and transfers it to acceptor proteins, recruiting repair enzymes. However, in cases of severe DNA damage, such as ischemia, hyperactivation of PARP1 leads to the depletion of NAD+ and ATP, triggering cell death through necrosis or apoptosis. Additionally, PAR is involved in double-strand break (DSB) repair by recruiting ATM, MRE11, and topoisomerase 1, which are key players in the DSB repair pathway.

Currently, all PARP inhibitors (PARPi) in development are designed to inhibit both PARP1 and PARP2. Although nicotinamide's ability to inhibit PARP activity was first noted in 1971, significant advancements in this field have been made in recent years. The first-generation PARP inhibitors were based on nicotinamide analogs. Today, PARP inhibitors are widely studied in combination therapies, where they function as sensitizers to chemotherapy, immunotherapy, and targeted therapies by impairing DNA damage repair mechanisms. Additionally, certain targeted treatments, such as MEK inhibitors, have been shown to enhance tumor cell sensitivity and overcome resistance to PARP inhibitors, further expanding their therapeutic potential.

Find out more about PARP Inhibitors medication @ https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

PARP Inhibitors Treatment Analysis: Drug Profile
Pamiparib: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies

AZD5305: AstraZeneca
AZD5305, a next-generation PARP1-selective inhibitor, in patients with tumors harboring specific homologous recombination repair gene mutations. AZD5305 is designed to selectively target PARP1, killing cancer cells by targeting tumor cell DNA damage repair mechanisms. This approach could allow PARP inhibitors to expand into new settings and offer new opportunities for combinations with DNA damage pathway activating agents such as ADCs. The next-generation PARP1 selective inhibitor, AZD5305, is progressing towards potential registrational trials for prostate cancer in combination with new hormonal agents, with data showing good tolerability at higher doses. Currently, the drug is being evaluated in clinical trials in patients with advanced solid tumors (Ovarian, breast, prostate, pancreatic cancer, and others).

Key PARP Inhibitors Therapies and Companies
• AZD5305: AstraZeneca
• Veliparib: AbbVie
• Pamiparib: BeiGene

Learn more about the novel and emerging PARP Inhibitors pipeline therapies @ https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

PARP Inhibitors Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

By Molecule Type
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Scope of the PARP Inhibitors Pipeline Report
• Coverage: Global
• Key PARP Inhibitors Companies: TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others.
• Key PARP Inhibitors Pipeline Therapies: AZD5305, Veliparib, Pamiparib, and others.

Dive deep into rich insights for drugs used for PARP Inhibitors treatment; visit @ https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. PARP Inhibitors Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. PARP Inhibitors Pipeline Therapeutics
6. PARP Inhibitors Pipeline: Late-Stage Products (Phase III)
7. PARP Inhibitors Pipeline: Late-Stage Products (Phase III)
8. PARP Inhibitors Pipeline: Mid-Stage Products (Phase II)
9. PARP Inhibitors Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.